Target Validation Information
Target ID T23172
Target Name Tyrosine-protein kinase JAK3
Target Type
Successful
Drug Potency against Target 6-o-tolylquinazolin-2-amine Drug Info IC50 = 9819 nM [528429]
Tofacitinib Drug Info IC50 = 1 nM [552773]
Atropisomer 1 Drug Info IC50 = 1530 nM [530583]
Action against Disease Model Tofacitinib A specific orally active inhibitor of JAK3, CP-690,550, significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants. CP-690,550 treatment was not associated with hypertension, hyperlipidemia, or lymphoproliferative disease. On the basis of these preclinical results, we believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in h uMan organ transplantation and in other clinical setting [552391] Drug Info
The Effect of Target Knockout, Knockdown or Genetic Variations JAK3 knockout mice and JAK3 deficient patients cannot signal through the interleukin-2,4,7,9,or 15 receptors and suffer from severe combined immunodeficiency (SCID).JAKl and JAK2 knockout mice do not survive,their cells again showing distinct patterns of cytokine signaling deficits.Dificent IL-2,IL-4,IL-7 in JAK3-/- knockout mice [552391]
References
Ref 552391Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003 Oct 31;302(5646):875-8.
Ref 528429J Med Chem. 2006 Sep 21;49(19):5671-86.Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
Ref 552773A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008 Jan;26(1):127-32. doi: 10.1038/nbt1358.
Ref 530583J Med Chem. 2009 Dec 24;52(24):7938-41.Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.